Upcoming Meetings: FDA Anesthesiology and Respiratory Therapy Devices Panel
This article was originally published in The Gray Sheet
FDA Anesthesiology and Respiratory Therapy Devices Panel: Slated to convene at 11 a.m. on Sept. 20 to discuss development of a guidance document on 510(k) submissions "for continuous positive air way pressure devices for treatment of obstructive sleep apnea," according to the agency's advisory committee information line. The panel also will hear presentations on FDA's 510(k) exemption of approximately 40 anesthesiology and respiratory therapy devices ("The Gray Sheet" Jan. 22, p. 6). FDA staffers note that there has been uncertainty as to whether certain devices are covered by the exemption or should be considered accessories to Class III products. The agency also wishes to obtain input on situations in which devices may technically meet the definition for exemption but nevertheless represent novel technologies that require FDA review. The meeting will take place at FDA offices at 9200 Corporate Blvd. in Rockville, Maryland. For further information, contact FDA's Michael Bazaral at 301/443-8609...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.